Indegene Limited (INDGN) Fair Value & Analysis
Healthcare · IN · Market cap ₹124B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated yesterday
Share price −2.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹428.62 – ₹596.68 · fair‑value band ₹249.75 – ₹455.08 · the ₹514.45 price screens above the ₹333.00 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Indegene Limited (INDGN) currently trades at ₹514.45, while our model-based Fair Value estimate is ₹333.00 — implying the stock looks roughly 35.3% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Indegene Limited generated revenue of ₹35.1B at a net margin of 11.4%. Revenue grew 32.8% year over year. It earns a return on equity of 13.9%. The balance sheet holds a net cash position of ₹2.4B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Indegene Limited reported revenue of ₹35.1B in FY2026 versus ₹16.6B in FY2022, a compound +20.5%/yr. Reported net income was ₹4.0B in FY2026, compounding +24.9%/yr from FY2022.
Is INDGN fairly valued? → Check now
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $163.76 | $103.58 | -37% |
| Pro Medicus Limited PME | A$172.80 | A$32.25 | -81% |
| BrightSpring Health Services, Inc BTSG | $57.40 | $23.87 | -58% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $89.72 | $54.47 | -39% |
| M3, Inc MTHRY | $5.03 | $7.44 | +48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Indegene Limited (INDGN) undervalued?
What is the fair value of INDGN?
What is the quality score of INDGN?
What is the revenue of Indegene Limited (INDGN)?
What is the net profit margin of INDGN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.